Technical Analysis for ZNTL - Zentalis Pharmaceuticals, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Crossed Above 20 DMA | Bullish | -0.04% | |
Golden Cross | Bullish | -0.04% | |
Calm After Storm | Range Contraction | -0.04% | |
NR7 | Range Contraction | -0.04% | |
NR7-2 | Range Contraction | -0.04% | |
Narrow Range Bar | Range Contraction | -0.04% | |
Fell Below 20 DMA | Bearish | 2.02% | |
Calm After Storm | Range Contraction | 2.02% | |
NR7 | Range Contraction | 2.02% | |
NR7-2 | Range Contraction | 2.02% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
Up 1% | about 4 hours ago |
20 DMA Support | about 4 hours ago |
Rose Above Previous Day's High | about 4 hours ago |
20 DMA Resistance | about 4 hours ago |
Down 2 % | about 4 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/08/2023
Zentalis Pharmaceuticals LLC is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin Bunker on December 23, 2014 and is headquartered in New York, NY.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Drugs Breast Cancer Treatment Of Breast Cancer Tyrosine Kinase Receptors Epidermal Growth Factor Receptor Hormones Her2 Her2/Neu Transcription Factors Molecule Therapeutics Estrogen Antiestrogens Estrogen Receptor Metastatic Breast Cancer Receptor Positive Selective Estrogen Receptor Degraders Intracellular Receptors
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Drugs Breast Cancer Treatment Of Breast Cancer Tyrosine Kinase Receptors Epidermal Growth Factor Receptor Hormones Her2 Her2/Neu Transcription Factors Molecule Therapeutics Estrogen Antiestrogens Estrogen Receptor Metastatic Breast Cancer Receptor Positive Selective Estrogen Receptor Degraders Intracellular Receptors
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 32.24 |
52 Week Low | 15.57 |
Average Volume | 863,788 |
200-Day Moving Average | 21.97 |
50-Day Moving Average | 21.98 |
20-Day Moving Average | 26.10 |
10-Day Moving Average | 26.87 |
Average True Range | 1.78 |
RSI (14) | 55.56 |
ADX | 41.62 |
+DI | 27.65 |
-DI | 10.17 |
Chandelier Exit (Long, 3 ATRs) | 26.13 |
Chandelier Exit (Short, 3 ATRs) | 26.24 |
Upper Bollinger Bands | 29.92 |
Lower Bollinger Band | 22.29 |
Percent B (%b) | 0.52 |
BandWidth | 29.23 |
MACD Line | 1.31 |
MACD Signal Line | 1.63 |
MACD Histogram | -0.3223 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 27.43 | ||||
Resistance 3 (R3) | 27.34 | 26.86 | 27.24 | ||
Resistance 2 (R2) | 26.86 | 26.57 | 26.91 | 27.17 | |
Resistance 1 (R1) | 26.57 | 26.38 | 26.72 | 26.66 | 27.11 |
Pivot Point | 26.09 | 26.09 | 26.16 | 26.13 | 26.09 |
Support 1 (S1) | 25.79 | 25.79 | 25.94 | 25.88 | 25.43 |
Support 2 (S2) | 25.31 | 25.61 | 25.36 | 25.37 | |
Support 3 (S3) | 25.02 | 25.31 | 25.30 | ||
Support 4 (S4) | 25.11 |